- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01177813
Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 and Sitagliptin Administered Orally Over 24 Weeks, in Drug naïve Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Diet and Exercise
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Bruxelles, België
- 1245.20.32008 Boehringer Ingelheim Investigational Site
-
Bruxelles, België
- 1245.20.32011 Boehringer Ingelheim Investigational Site
-
Bruxelles, België
- 1245.20.32023 Boehringer Ingelheim Investigational Site
-
De Pinte, België
- 1245.20.32003 Boehringer Ingelheim Investigational Site
-
Deurne, België
- 1245.20.32015 Boehringer Ingelheim Investigational Site
-
Deurne, België
- 1245.20.32016 Boehringer Ingelheim Investigational Site
-
Gozée, België
- 1245.20.32025 Boehringer Ingelheim Investigational Site
-
Landen, België
- 1245.20.32022 Boehringer Ingelheim Investigational Site
-
Leopoldsburg, België
- 1245.20.32019 Boehringer Ingelheim Investigational Site
-
Linkebeek, België
- 1245.20.32024 Boehringer Ingelheim Investigational Site
-
Mouscron, België
- 1245.20.32021 Boehringer Ingelheim Investigational Site
-
Retie, België
- 1245.20.32027 Boehringer Ingelheim Investigational Site
-
Sint-Gillis-Waas, België
- 1245.20.32020 Boehringer Ingelheim Investigational Site
-
Tielt, België
- 1245.20.32018 Boehringer Ingelheim Investigational Site
-
Tremelo, België
- 1245.20.32026 Boehringer Ingelheim Investigational Site
-
-
-
-
British Columbia
-
Chilliwack, British Columbia, Canada
- 1245.20.20011 Boehringer Ingelheim Investigational Site
-
Victoria, British Columbia, Canada
- 1245.20.20018 Boehringer Ingelheim Investigational Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
- 1245.20.20015 Boehringer Ingelheim Investigational Site
-
-
New Brunswick
-
Moncton, New Brunswick, Canada
- 1245.20.20012 Boehringer Ingelheim Investigational Site
-
-
Newfoundland and Labrador
-
Mount Pearl, Newfoundland and Labrador, Canada
- 1245.20.20016 Boehringer Ingelheim Investigational Site
-
St. John's, Newfoundland and Labrador, Canada
- 1245.20.20008 Boehringer Ingelheim Investigational Site
-
-
Ontario
-
Barrie, Ontario, Canada
- 1245.20.20001 Boehringer Ingelheim Investigational Site
-
Hamilton, Ontario, Canada
- 1245.20.20019 Boehringer Ingelheim Investigational Site
-
London, Ontario, Canada
- 1245.20.20010 Boehringer Ingelheim Investigational Site
-
London, Ontario, Canada
- 1245.20.20017 Boehringer Ingelheim Investigational Site
-
Markham, Ontario, Canada
- 1245.20.20003 Boehringer Ingelheim Investigational Site
-
Newmarket, Ontario, Canada
- 1245.20.20009 Boehringer Ingelheim Investigational Site
-
Ottawa, Ontario, Canada
- 1245.20.20013 Boehringer Ingelheim Investigational Site
-
Strathroy, Ontario, Canada
- 1245.20.20005 Boehringer Ingelheim Investigational Site
-
Toronto, Ontario, Canada
- 1245.20.20002 Boehringer Ingelheim Investigational Site
-
Toronto, Ontario, Canada
- 1245.20.20006 Boehringer Ingelheim Investigational Site
-
-
Prince Edward Island
-
Charlottetown, Prince Edward Island, Canada
- 1245.20.20014 Boehringer Ingelheim Investigational Site
-
Montague, Prince Edward Island, Canada
- 1245.20.20007 Boehringer Ingelheim Investigational Site
-
-
Quebec
-
Trois Rivieres, Quebec, Canada
- 1245.20.20021 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Beijing, China
- 1245.20.86007 Boehringer Ingelheim Investigational Site
-
Beijing, China
- 1245.20.86008 Boehringer Ingelheim Investigational Site
-
Guangzhou, China
- 1245.20.86001 Boehringer Ingelheim Investigational Site
-
Guangzhou, China
- 1245.20.86002 Boehringer Ingelheim Investigational Site
-
Guangzhou, China
- 1245.20.86003 Boehringer Ingelheim Investigational Site
-
Guiyang, China
- 1245.20.86012 Boehringer Ingelheim Investigational Site
-
Hangzhou, China
- 1245.20.86020 Boehringer Ingelheim Investigational Site
-
Jinan, China
- 1245.20.86049 Boehringer Ingelheim Investigational Site
-
Jingzhou, China
- 1245.20.86018 Boehringer Ingelheim Investigational Site
-
Nanchang, China
- 1245.20.86019 Boehringer Ingelheim Investigational Site
-
Nanjing, China
- 1245.20.86010 Boehringer Ingelheim Investigational Site
-
Nanjing, China
- 1245.20.86043 Boehringer Ingelheim Investigational Site
-
QingDao, China
- 1245.20.86016 Boehringer Ingelheim Investigational Site
-
Shanghai, China
- 1245.20.86004 Boehringer Ingelheim Investigational Site
-
Shanghai, China
- 1245.20.86005 Boehringer Ingelheim Investigational Site
-
Shanghai, China
- 1245.20.86006 Boehringer Ingelheim Investigational Site
-
Shenyang, China
- 1245.20.86057 Boehringer Ingelheim Investigational Site
-
Shiyan, China
- 1245.20.86017 Boehringer Ingelheim Investigational Site
-
Suzhou, China
- 1245.20.86013 Boehringer Ingelheim Investigational Site
-
Taiyuan, China
- 1245.20.86015 Boehringer Ingelheim Investigational Site
-
Wuhan, China
- 1245.20.86009 Boehringer Ingelheim Investigational Site
-
Xi'An, China
- 1245.20.86011 Boehringer Ingelheim Investigational Site
-
Xiamen, China
- 1245.20.86014 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Dresden, Duitsland
- 1245.20.49013 Boehringer Ingelheim Investigational Site
-
Düsseldorf, Duitsland
- 1245.20.49016 Boehringer Ingelheim Investigational Site
-
Frankfurt, Duitsland
- 1245.20.49015 Boehringer Ingelheim Investigational Site
-
Haag, Duitsland
- 1245.20.49019 Boehringer Ingelheim Investigational Site
-
Hohenmölsen, Duitsland
- 1245.20.49020 Boehringer Ingelheim Investigational Site
-
Köthen, Duitsland
- 1245.20.49014 Boehringer Ingelheim Investigational Site
-
Neuwied, Duitsland
- 1245.20.49002 Boehringer Ingelheim Investigational Site
-
Nürnberg, Duitsland
- 1245.20.49008 Boehringer Ingelheim Investigational Site
-
Schauenburg, Duitsland
- 1245.20.49022 Boehringer Ingelheim Investigational Site
-
St. Ingbert/Oberwürzbach, Duitsland
- 1245.20.49017 Boehringer Ingelheim Investigational Site
-
Unterschneidheim, Duitsland
- 1245.20.49003 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Co. Cork, Ierland
- 1245.20.35302 Boehringer Ingelheim Investigational Site
-
Co. Galway, Ierland
- 1245.20.35305 Boehringer Ingelheim Investigational Site
-
Co. Wexford, Ierland
- 1245.20.35303 Boehringer Ingelheim Investigational Site
-
Offaly, Ierland
- 1245.20.35304 Boehringer Ingelheim Investigational Site
-
Wexford, Ierland
- 1245.20.35306 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bangalore, Indië
- 1245.20.91005 Boehringer Ingelheim Investigational Site
-
Bangalore, Indië
- 1245.20.91006 Boehringer Ingelheim Investigational Site
-
Bangalore, Indië
- 1245.20.91008 Boehringer Ingelheim Investigational Site
-
Belgaum, Indië
- 1245.20.91003 Boehringer Ingelheim Investigational Site
-
Chennai, Indië
- 1245.20.91004 Boehringer Ingelheim Investigational Site
-
Chennai, Indië
- 1245.20.91009 Boehringer Ingelheim Investigational Site
-
Mumbai, Indië
- 1245.20.91002 Boehringer Ingelheim Investigational Site
-
Mumbai, Maharastra, Indië
- 1245.20.91007 Boehringer Ingelheim Investigational Site
-
Nagpur, Indië
- 1245.20.91010 Boehringer Ingelheim Investigational Site
-
Tamil Nadu, Indië
- 1245.20.91001 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Chiyoda-ku, Tokyo, Japan
- 1245.20.81007 Boehringer Ingelheim Investigational Site
-
Chuo-ku, Tokyo, Japan
- 1245.20.81001 Boehringer Ingelheim Investigational Site
-
Chuo-ku, Tokyo, Japan
- 1245.20.81002 Boehringer Ingelheim Investigational Site
-
Ebetsu, Hokkaido, Japan
- 1245.20.81005 Boehringer Ingelheim Investigational Site
-
Kamakura, Kanagawa, Japan
- 1245.20.81004 Boehringer Ingelheim Investigational Site
-
Minato-ku, Tokyo, Japan
- 1245.20.81003 Boehringer Ingelheim Investigational Site
-
Shinjuku-ku, Tokyo, Japan
- 1245.20.81006 Boehringer Ingelheim Investigational Site
-
Shinjuku-ku, Tokyo, Japan
- 1245.20.81008 Boehringer Ingelheim Investigational Site
-
Suita, Osaka, Japan
- 1245.20.81009 Boehringer Ingelheim Investigational Site
-
Ube, Yamaguchi, Japan
- 1245.20.81010 Boehringer Ingelheim Investigational Site
-
Urasoe, Okinawa, Japan
- 1245.20.81012 Boehringer Ingelheim Investigational Site
-
Urasoe, Okinawa, Japan
- 1245.20.81013 Boehringer Ingelheim Investigational Site
-
-
-
-
Arizona
-
Mesa, Arizona, Verenigde Staten
- 1245.20.10124 Boehringer Ingelheim Investigational Site
-
Phoenix, Arizona, Verenigde Staten
- 1245.20.10108 Boehringer Ingelheim Investigational Site
-
-
Arkansas
-
Hot Springs, Arkansas, Verenigde Staten
- 1245.20.10150 Boehringer Ingelheim Investigational Site
-
-
California
-
Chino, California, Verenigde Staten
- 1245.20.10154 Boehringer Ingelheim Investigational Site
-
Santa Ana, California, Verenigde Staten
- 1245.20.10009 Boehringer Ingelheim Investigational Site
-
West Hills, California, Verenigde Staten
- 1245.20.10131 Boehringer Ingelheim Investigational Site
-
-
Colorado
-
Northglenn, Colorado, Verenigde Staten
- 1245.20.10038 Boehringer Ingelheim Investigational Site
-
-
Florida
-
Clearwater, Florida, Verenigde Staten
- 1245.20.10137 Boehringer Ingelheim Investigational Site
-
Miami, Florida, Verenigde Staten
- 1245.20.10006 Boehringer Ingelheim Investigational Site
-
Plantation, Florida, Verenigde Staten
- 1245.20.10085 Boehringer Ingelheim Investigational Site
-
Tampa, Florida, Verenigde Staten
- 1245.20.10078 Boehringer Ingelheim Investigational Site
-
-
Georgia
-
Decatur, Georgia, Verenigde Staten
- 1245.20.10080 Boehringer Ingelheim Investigational Site
-
-
Indiana
-
Avon, Indiana, Verenigde Staten
- 1245.20.10128 Boehringer Ingelheim Investigational Site
-
Fishers, Indiana, Verenigde Staten
- 1245.20.10060 Boehringer Ingelheim Investigational Site
-
Indianapolis, Indiana, Verenigde Staten
- 1245.20.10065 Boehringer Ingelheim Investigational Site
-
-
Kansas
-
Arkansas City, Kansas, Verenigde Staten
- 1245.20.10117 Boehringer Ingelheim Investigational Site
-
Wichita, Kansas, Verenigde Staten
- 1245.20.10039 Boehringer Ingelheim Investigational Site
-
-
Kentucky
-
Louisville, Kentucky, Verenigde Staten
- 1245.20.10146 Boehringer Ingelheim Investigational Site
-
-
Massachusetts
-
Watertown, Massachusetts, Verenigde Staten
- 1245.20.10144 Boehringer Ingelheim Investigational Site
-
-
New Jersey
-
Brick, New Jersey, Verenigde Staten
- 1245.20.10115 Boehringer Ingelheim Investigational Site
-
-
Ohio
-
Carlisle, Ohio, Verenigde Staten
- 1245.20.10129 Boehringer Ingelheim Investigational Site
-
Cincinnati, Ohio, Verenigde Staten
- 1245.20.10045 Boehringer Ingelheim Investigational Site
-
Cincinnati, Ohio, Verenigde Staten
- 1245.20.10119 Boehringer Ingelheim Investigational Site
-
Gallipolis, Ohio, Verenigde Staten
- 1245.20.10130 Boehringer Ingelheim Investigational Site
-
-
Texas
-
Houston, Texas, Verenigde Staten
- 1245.20.10089 Boehringer Ingelheim Investigational Site
-
Hurst, Texas, Verenigde Staten
- 1245.20.10151 Boehringer Ingelheim Investigational Site
-
San Antonio, Texas, Verenigde Staten
- 1245.20.10155 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Lugano, Zwitserland
- 1245.20.41004 Boehringer Ingelheim Investigational Site
-
Rorschach, Zwitserland
- 1245.20.41003 Boehringer Ingelheim Investigational Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion criteria:
- Diagnosis of type 2 diabetes mellitus prior to informed consent;
- Male and female patients on diet and exercise regimen who are drug-naïve;
- HbA1c >= 7.0% and <= 10.0% at Visit 1 (screening) for randomised treatment; HbA1c > 10.0% at visit 1 (screening) for the open-label BI 10773 arm;
- Age >= 20 (Japan); Age >= 18 (countries other than Japan);
- BMI <= 45 kg/m2 at Visit 1 (screening);
- Signed and dated written informed consent by date of Visit 1
Exclusion criteria:
- Uncontrolled hyperglycaemia;
- Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or TIA within 3 months prior to informed consent;
- Indication of liver disease, either ALT, AST, or alkaline phosphatase above 3 x ULN;
- Impaired renal function (eGFR<50 ml/min);
- Bariatric surgery within the past two years or other GI surgeries;
- Medical history of cancer;
- Contraindications to sitagliptin;
- Blood dyscrasias or any disorders causing haemolysis or unstable red blood cell;
- Treatment with any anti-diabetes drug within 12 weeks prior to randomisation;
- Treatment with anti-obesity drugs or any other treatment leading to unstable body weight;
- Current treatment with systemic steroids or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except T2DM;
- Pre-menopausal women who are nursing or pregnant or are of child-bearing potential and not practicing an acceptable method of birth control;
- Alcohol or drug abuse;
- Intake of an investigational drug in another trial within 30 days prior to intake of study medication in this trial;
- Any other clinical condition that would jeopardize patients safety while participating in this clinical trial
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: BI 10773 low dose
Patients receive BI 10773 low dose tablets once daily
|
BI 10773 laaggedoseerde tablet eenmaal daags
placebo tablets once daily
placebo tablets once daily
|
|
Experimenteel: BI 10773 high dose
Patients receive BI 10773 high dose tablets once daily
|
placebo tablets once daily
placebo tablets once daily
BI 10773 high dose tablets once daily
|
|
Placebo-vergelijker: Placebo
Patients receive tablets identical to those containing BI 10773 low dose and high dose and to Sitagliptin
|
placebo tablets once daily
placebo tablets once daily
placebo tablets once daily
|
|
Actieve vergelijker: Sitagliptin 100 mg
Patients receive Sitagliptin 100 mg tablets once daily
|
placebo tablets once daily
placebo tablets once daily
Sitagliptin tablets 100 mg once daily
|
|
Experimenteel: BI 10773 high dose open label
Patients receive BI 10773 high dose tablets open label once daily
|
Patients receive BI 10773 high dose tablets open label once daily
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 24 Weeks
Tijdsspanne: Baseline and day 169
|
The term "baseline" refers to the last observation before the start of randomised trial treatment (or of open-label treatment for the open-label arm). In this endpoint, the "measured values" show unadjusted values, whereas the statistical analyses show adjusted values. Statistics for open-label group are descriptive. |
Baseline and day 169
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change From Baseline to Week 24 in Body Weight
Tijdsspanne: Baseline and day 169
|
The term "baseline" refers to the last observation before the start of randomised trial treatment (or of open-label treatment for the open-label arm). In this endpoint, the "measured values" show unadjusted values, whereas the statistical analyses show adjusted values. Statistics for open-label group are descriptive. |
Baseline and day 169
|
|
Change From Baseline to Week 24 in Systolic and Diastolic Blood Pressure (SBP and DBP)
Tijdsspanne: Baseline and week 24
|
The term "baseline" refers to the last observation before the start of randomised trial treatment (or of open-label treatment for the open-label arm). In this endpoint, the "measured values" show unadjusted values, whereas the statistical analyses show adjusted values. Statistics for open-label group are descriptive. For blood pressure, data following changes in antihypertensive therapy is censored, in the same way that data following initiation of rescue medication is censored. |
Baseline and week 24
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Confirmed Hypoglycaemic Adverse Events
Tijdsspanne: From first drug intake until 7 days after last medication intake, up to 219 days
|
Confirmed hypoglycaemic events refer to all hypoglycaemic events, that had a glucose value <= 70 ml/dL or where assistance was required. Symptomatic hypoglycaemic events were to be reported as adverse events. Patients can be counted in more than one category. |
From first drug intake until 7 days after last medication intake, up to 219 days
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Publicaties en nuttige links
Algemene publicaties
- Tuttle KR, Levin A, Nangaku M, Kadowaki T, Agarwal R, Hauske SJ, Elsasser A, Ritter I, Steubl D, Wanner C, Wheeler DC. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care. 2022 Jun 2;45(6):1445-1452. doi: 10.2337/dc21-2034.
- Cherney D, Lund SS, Perkins BA, Groop PH, Cooper ME, Kaspers S, Pfarr E, Woerle HJ, von Eynatten M. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016 Sep;59(9):1860-70. doi: 10.1007/s00125-016-4008-2. Epub 2016 Jun 17.
- Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, Broedl UC; EMPA-REG MONO trial investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013 Nov;1(3):208-19. doi: 10.1016/S2213-8587(13)70084-6. Epub 2013 Sep 9.
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Glucosemetabolismestoornissen
- Metabole ziekten
- Endocriene systeemziekten
- Suikerziekte
- Diabetes mellitus, type 2
- Hypoglycemische middelen
- Fysiologische effecten van medicijnen
- Moleculaire mechanismen van farmacologische werking
- Enzymremmers
- Hormonen
- Hormonen, hormoonvervangers en hormoonantagonisten
- Proteaseremmers
- Incretines
- Natrium-Glucose Transporter 2-remmers
- Dipeptidyl-peptidase IV-remmers
- Empagliflozine
- Sitagliptinefosfaat
Andere studie-ID-nummers
- 1245.20
- 2009-016243-20 (EudraCT-nummer: EudraCT)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .